Kovitz Investment Group Partners LLC Raises Stock Position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Kovitz Investment Group Partners LLC increased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,740 shares of the biopharmaceutical company’s stock after purchasing an additional 95 shares during the period. Kovitz Investment Group Partners LLC’s holdings in Alexion Pharmaceuticals were worth $771,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of ALXN. LSV Asset Management lifted its stake in Alexion Pharmaceuticals by 312.0% during the 2nd quarter. LSV Asset Management now owns 3,499,434 shares of the biopharmaceutical company’s stock valued at $392,776,000 after acquiring an additional 2,650,007 shares during the period. BlackRock Inc. lifted its stake in shares of Alexion Pharmaceuticals by 12.2% in the 2nd quarter. BlackRock Inc. now owns 18,527,930 shares of the biopharmaceutical company’s stock worth $2,079,578,000 after purchasing an additional 2,016,954 shares during the period. FMR LLC lifted its stake in shares of Alexion Pharmaceuticals by 9.4% in the 2nd quarter. FMR LLC now owns 13,000,451 shares of the biopharmaceutical company’s stock worth $1,459,169,000 after purchasing an additional 1,117,179 shares during the period. Epoch Investment Partners Inc. bought a new position in shares of Alexion Pharmaceuticals in the 2nd quarter worth approximately $73,136,000. Finally, Point72 Asset Management L.P. lifted its stake in shares of Alexion Pharmaceuticals by 88.6% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,211,342 shares of the biopharmaceutical company’s stock worth $135,961,000 after purchasing an additional 568,997 shares during the period. Institutional investors and hedge funds own 84.22% of the company’s stock.

ALXN has been the topic of several recent research reports. SVB Leerink increased their price objective on shares of Alexion Pharmaceuticals from $159.00 to $163.00 and gave the stock an “outperform” rating in a research note on Friday, October 30th. Stifel Nicolaus lowered their price objective on shares of Alexion Pharmaceuticals from $120.00 to $117.00 and set a “hold” rating on the stock in a research note on Tuesday, September 1st. Oppenheimer reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Thursday, July 30th. Smith Barney Citigroup increased their price objective on shares of Alexion Pharmaceuticals from $145.00 to $157.00 in a research note on Thursday, November 5th. Finally, UBS Group assumed coverage on shares of Alexion Pharmaceuticals in a report on Wednesday, October 28th. They issued a “neutral” rating and a $133.00 target price for the company. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $143.72.

Shares of Alexion Pharmaceuticals stock opened at $121.38 on Friday. The firm has a market cap of $26.56 billion, a P/E ratio of 28.36, a P/E/G ratio of 0.98 and a beta of 1.31. The company has a current ratio of 3.81, a quick ratio of 3.26 and a debt-to-equity ratio of 0.22. Alexion Pharmaceuticals, Inc. has a 12 month low of $72.67 and a 12 month high of $128.57. The stock’s fifty day moving average price is $121.65 and its 200-day moving average price is $111.71.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $3.24 EPS for the quarter, beating the consensus estimate of $2.60 by $0.64. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.43 billion. Alexion Pharmaceuticals had a return on equity of 23.16% and a net margin of 16.32%. The business’s revenue for the quarter was up 25.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.79 earnings per share. Analysts forecast that Alexion Pharmaceuticals, Inc. will post 11.14 earnings per share for the current year.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).

Featured Article: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.